Although there have been significant advances in the treatment of visceral leishmaniasis (VL)
and several novel compounds are currently in pre-clinical and clinical development for this …

Leishmaniasis is a disease complex caused by 20 species of protozoan parasites belonging
to the genus Leishmania. In humans, it has two main clinical forms, visceral leishmaniasis (…

Leishmaniasis is a tropical infectious disease caused by the protozoan Leishmania parasite.
The disease is transmitted by female sand flies and, depending on the infecting parasite …

Leishmaniasis is widely regarded as a vaccine-preventable disease, but the costs required
to reach pivotal Phase 3 studies and uncertainty about which candidate vaccines should be …

Objectives Drugs for Neglected Diseases initiative (DNDi) has identified three chemical lead
series, the nitroimidazoles, benzoxaboroles and aminopyrazoles, as innovative treatments …

… Katrien Van Bocxlaer is supported by a fellowship awarded from the Research Council
United Kingdom Grand Challenges Research Funder under grant agreement ‘A Global Network …

Objectives Pathological disorder can disrupt the barrier integrity of the skin, thereby altering
the drug delivery from topical formulations to the target site. Cutaneous leishmaniasis (CL) is …

… Furthermore, the permeability coefficient (K p ) for the drug formulation in water was statistically
significantly lower compared to K p for the DMI and OSAL formulation. This indicated that …

Fungisome ® (F), a liposomal amphotericin B (AmB) product, is marketed in India as a safe
and effective therapeutic for the parasitic infection visceral leishmaniasis. Its potential in the …

Cutaneous leishmaniasis (CL) is caused by several species of the protozoan parasite
Leishmania , affecting an estimated 10 million people worldwide. Previously reported strategies …